Brief: Dawnrays Pharmaceutical says Suzhou Dawnrays terminates master agency agreement with party
15/07/2016 12:39
July 15 (Reuters) - Dawnrays Pharmaceutical Holdings Ltd 2348.HK : * Pharma-business updates termination of master agency agreement * Says Suzhou Dawnrays and Agency agreed to terminate national master agency agreement with effect from July 2016 * Updates in relation to sales of 0.5mg "Leiyide" manufactured by company's unit * Source text for Eikon ID:nHKSbPvzz1 ((For more news, please click here 2348.HK )) ((Bengaluru Newsroom; +91 80 6749 1130))
Recent news on Dawnrays Pharmaceutical (Holdings)
See all newsBrief: Dawnrays Pharmaceutical Says Suzhou Dawnrays Commits To Invest Up To RMB100 Mln In Partnership
Brief: Dawnrays Pharmaceutical (Holdings) Final Dividend Of Hk$0.048 Per Share
Brief: Dawnrays Pharmaceutical Reports HY Net Income Attributable Of RMB104.6 MLN
Brief: Dawnrays Pharmaceutical (Holdings) Posts FY Profit Attributable Of Rmb564.9 Million
Brief: Dawnrays Pharmaceutical (Holdings) Appoints Yu Liwei To Act As CEO